Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 3Recruiting 2Not yet recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Neuroendocrine 1

Interventions

Etoposide 23Cisplatin 15Carboplatin 13Irinotecan 12apatinib 11anlotinib 10durvalumab 7Topotecan 6toripalimab 4surufatinib 4sintilimab 4atezolizumab 4Temozolomide 4Drug Therapy 4tislelizumab 3lobaplatin 3camrelizumab 3Simvastatin 3Radiotherapy 3Ifosfamide 3Albumin-Bound Paclitaxel 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2olaparib 2niraparib 2isophosphamide mustard 2avelumab 2X-Rays 2Platinum 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Small Cell Lung Carcinoma × EC regimen × Clear all
NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.

Phase 2/3 Unknown
313 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡